Fig. 4: Fibrosis was reduced after CD5/βLNP-FAPCAR 2.2 therapy in young and aged mice. | Nature Communications

Fig. 4: Fibrosis was reduced after CD5/βLNP-FAPCAR 2.2 therapy in young and aged mice.

From: Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile

Fig. 4

A Masson and picrosirius red staining of fibrotic areas (Scale bar: 100 and 200 μm). B, C Quantified changes of fibrotic areas (B) and Ashcroft scale (C) (n = 5,5,12,10,10,9). D Hydroxyproline (HYP) assay for quantification of collagen content. (n = 4,4,10,10,10,7). E Elasticity modulus assay of the entire lung tissue in healthy, fibrotic, and treatment groups by the Mechanical Testing System (n = 4,4,5). F–H CD5/βLNP-FAPCAR 2.2 anti-fibrotic assay in the fibrotic model of aged (16 month) mice: BW (F), survival rate (G), and lung coefficients (H) (n = 4,4,8,8,8). The survival rate was analyzed using the log-rank (Mantel-Cox) test. I–M Digital photos (I), micro-CT images (J, K) (n = 4), quantification of fibrosis area using the Masson staining (L) (n = 4,4,8,8,7) and HYP assay (M) (n = 4,4,7,7,7) showing the significant reduction of fibrosis after CD5/βLNP-FAPCAR 2.2 therapy. ‘n’ means independent biological replications. The values are the means ± SDs. *P < 0.05. P-value determined by one-way ANOVA followed by Tukey’s multiple comparisons test (B–E, H, I, K–M). Source data are provided as a Source Data file. Created in BioRender (F)65.

Back to article page